Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Et
![Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction ... Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction ...](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fsj.ijir.3901139/MediaObjects/41443_2004_Article_BF3901139_Fig3_HTML.gif)
Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction ...
Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study
![Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics - ScienceDirect Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0731708520302375-gr1.jpg)
Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics - ScienceDirect
![These highlights do not include all the information needed to use VYLEESI™ safely and effectively. See full prescribing information for VYLEESI™. VYLEESI (bremelanotide injection), for subcutaneous use Initial U.S. Approval: 2019 These highlights do not include all the information needed to use VYLEESI™ safely and effectively. See full prescribing information for VYLEESI™. VYLEESI (bremelanotide injection), for subcutaneous use Initial U.S. Approval: 2019](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=vyleesi-05.jpg&id=536911)